Skip to content

Author

R. Finn

We have 2 of 25 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies.

BACKGROUND Advances in systemic therapy for advanced hepatocellular carcinoma (HCC) have fuelled a growing interest in evaluating these therapies in earlier stages of disease. However, trial design remains challenging due to the marked clinical and biological heterogeneity of early-stage and intermediate-stage HCC. O...

M. Yarchoan, Josep M. Llovet, R. K. Kelley et al. · 0 citations
Review Open access Sep 2026

Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial.

BACKGROUND & AIMS First-line nivolumab demonstrated a higher objective response rate (ORR) and favorable safety profile vs. sorafenib in advanced HCC in the phase 3 CheckMate 459 trial; however, no significant improvement in overall survival (OS) was observed. Here, we report exploratory biomarker analyses from CheckMa...

J. Neely, Jin Yao, M. Kudo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.